Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario.
Saved in:
| Title: | Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario. |
|---|---|
| Authors: | Lorefice, Lorena (AUTHOR), Mellino, Paolo (AUTHOR), Frau, Jessica (AUTHOR), Coghe, Giancarlo (AUTHOR), Fenu, Giuseppe (AUTHOR), Cocco, Eleonora (AUTHOR) |
| Source: | Neurological Sciences. Aug2024, Vol. 45 Issue 8, p3951-3959. 9p. |
| Subjects: | Multiple sclerosis, John Cunningham virus, Natalizumab |
| Abstract: | Introduction: CD20-depleting therapies are a real milestone in the treatment of multiple sclerosis (MS). This study examined the ocrelizumab (OCR) use in patients with primary progressive (PP) and relapsing remitting (RR) MS, also evaluating the predictors of treatment response. Methods: Patients with MS treated with OCR between 2017 and 2022 were included, and OCR use trends examined. The patients' characteristics were assessed at baseline and after 24 months of OCR to assess the NEDA-3 status. Results: This study included 421 patients: 33 (7.9%) with PP and 388 (92.1%) with RR MS. Among these, 67 (17.3%) were naïve, while switchers from first- and second-line disease-modifying therapies (DMTs) were 199 (51.3%) and 122 (31.4%), respectively. An increasing trend in OCR use was reported. For six patients treated with rituximab, OCR was chosen to improve tolerability; for 390 switcher patients, the choice was due to ineffectiveness; and for 25, as an exit strategy from natalizumab due to JC virus positivity. NEDA-3 status was calculated for subjects exposed to 24 months of OCR and was achieved by 163/192 (84.9%) RR patients and 9/16 (56%) PP patients, with younger age (p = 0.048) and annualized relapse rate in the year previous to OCR (p = 0.005) emerging as determinants. For the 25 patients who switched to OCR after natalizumab, no clinical or MRI activity after 12 months was reported. Conclusion: OCR has been confirmed to be a highly efficacious option for patients with PP and RR MS, even proving to be a valid exit strategy for natalizumab. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: pbh DbLabel: Psychology and Behavioral Sciences Collection An: 178484330 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Lorefice%2C+Lorena%22">Lorefice, Lorena</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mellino%2C+Paolo%22">Mellino, Paolo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Frau%2C+Jessica%22">Frau, Jessica</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Coghe%2C+Giancarlo%22">Coghe, Giancarlo</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fenu%2C+Giuseppe%22">Fenu, Giuseppe</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cocco%2C+Eleonora%22">Cocco, Eleonora</searchLink> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Aug2024, Vol. 45 Issue 8, p3951-3959. 9p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22Multiple+sclerosis%22">Multiple sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22John+Cunningham+virus%22">John Cunningham virus</searchLink><br /><searchLink fieldCode="DE" term="%22Natalizumab%22">Natalizumab</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Introduction: CD20-depleting therapies are a real milestone in the treatment of multiple sclerosis (MS). This study examined the ocrelizumab (OCR) use in patients with primary progressive (PP) and relapsing remitting (RR) MS, also evaluating the predictors of treatment response. Methods: Patients with MS treated with OCR between 2017 and 2022 were included, and OCR use trends examined. The patients' characteristics were assessed at baseline and after 24 months of OCR to assess the NEDA-3 status. Results: This study included 421 patients: 33 (7.9%) with PP and 388 (92.1%) with RR MS. Among these, 67 (17.3%) were naïve, while switchers from first- and second-line disease-modifying therapies (DMTs) were 199 (51.3%) and 122 (31.4%), respectively. An increasing trend in OCR use was reported. For six patients treated with rituximab, OCR was chosen to improve tolerability; for 390 switcher patients, the choice was due to ineffectiveness; and for 25, as an exit strategy from natalizumab due to JC virus positivity. NEDA-3 status was calculated for subjects exposed to 24 months of OCR and was achieved by 163/192 (84.9%) RR patients and 9/16 (56%) PP patients, with younger age (p = 0.048) and annualized relapse rate in the year previous to OCR (p = 0.005) emerging as determinants. For the 25 patients who switched to OCR after natalizumab, no clinical or MRI activity after 12 months was reported. Conclusion: OCR has been confirmed to be a highly efficacious option for patients with PP and RR MS, even proving to be a valid exit strategy for natalizumab. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=178484330 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10072-024-07449-0 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 9 StartPage: 3951 Subjects: – SubjectFull: Multiple sclerosis Type: general – SubjectFull: John Cunningham virus Type: general – SubjectFull: Natalizumab Type: general Titles: – TitleFull: Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lorefice, Lorena – PersonEntity: Name: NameFull: Mellino, Paolo – PersonEntity: Name: NameFull: Frau, Jessica – PersonEntity: Name: NameFull: Coghe, Giancarlo – PersonEntity: Name: NameFull: Fenu, Giuseppe – PersonEntity: Name: NameFull: Cocco, Eleonora IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: Aug2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 15901874 Numbering: – Type: volume Value: 45 – Type: issue Value: 8 Titles: – TitleFull: Neurological Sciences Type: main |
| ResultId | 1 |
